

Tumor Cell Biology meeting 2014

Hotel 'de Werelt' Lunteren

Tuesday November 4th, 2014

09.00 Registration and coffee

10.00 Welcome by Frank van Leeuwen

Session I: Tumor-immunology and -microenvironment

Chairs: Paul Coffey and Boudewijn Burgering

10.15 Leukemia specific antibodies induce potent graft versus leukemia responses after allogeneic hematopoietic stem cell transplantation
M.A. Gillissen, AMC, Amsterdam

10.30 Biopsy-induced inflammation causes increased cell migration in gliomas
M. Alieva, Hubrecht Institute, Utrecht

10.45 Therapeutic synergy between macrophage blockade and chemotherapy elicits neutrophil-dependent therapy resistance
C. Salvagno, NKI, Amsterdam

11.00 Bone-marrow niche derived R-spondins facilitate Wnt/ β -catenin signalling in multiple myeloma via aberrantly expressed LGR4
H. van Andel, AMC, Amsterdam

11.15 Coffee/Tea

Session II: Gene regulation and genome organization

Chairs: Ruud Delwel and Roland Kuiper

- 11.45 Methylation-mediated silencing of microRNAs during hrHPV-induced transformation
S. Wilting, VUMC, Amsterdam
- 12.00 Essential role for non-canonical PRC1.1 in leukemia independent of the canonical PRC2/PRC1 axis
V. van den Boom, UMCG, Groningen
- 12.15 Integrated epigenomics identifies FZD10 as novel modulator for platinum sensitivity in high grade serous ovarian cancer
T. Tomar, UMCG, Groningen
- 12.30 Polycomb imbalance promotes non-small cell lung cancer progression
G. Gargiulo, NKI, Amsterdam
- 12.45 Defective sister chromatid cohesion sensitizes for APC/C inhibition
J. de Lange, VUMC, Amsterdam
- 13.00 lunch (14.00 meeting project leaders)**
- 14.30 **Invited lecture**
“Circumventing cancer stem cells resistance to therapy”
Jan Paul Medema, AMC, Amsterdam
- 15.15 **KWF presentation**
“Preview van de nieuwe beleidsvisie en werkwijze van KWF Kankerbestrijding”
Janna Hensing

Session III: Therapy(-resistance) and (pre-)clinical studies

Chairs: Arzu Umar and Steven de Jong

- 15.30 Epithelial-to-mesenchymal transition and therapy resistance in BRCA1-associated breast cancer
M. van Miltenburg, NKI, Amsterdam
- 15.45 The majority of RAS pathway mutations detected in relapsed B-cell precursor acute lymphoblastic leukemia are present in major or minor subclones at diagnosis
J. Yu, Radboudumc, Nijmegen
- 16.00 In vitro evaluation of BMS-754807, a small molecule inhibitor of the IGF-1R, IR and c-Met receptor as a therapeutic agent in ovarian cancer
J.A.L. Visser, UMCG, Groningen
- 16.15 Coffee/Tea**
- 16.45 Targeting BCR-independent proliferation of CLL cells
E. Slinger, AMC, Amsterdam
- 17.00 Characterization of novel mouse cell lines to study the role of B-cell receptor signaling in development of Chronic Lymphocytic Leukemia
S. Pal Singh, Erasmus MC, Rotterdam
- 17.15 Establishment of a patient-derived xenograft platform for metastatic melanoma
K. Kemper, NKI, Amsterdam

- 17.30 Long-term inhibition of HER2 induces epithelial-mesenchymal transition in esophageal cancer cells
E. Ebbing, AMC, Amsterdam
- 17.45 A 4-protein profile predicts tamoxifen treatment outcome in recurrent ER+ breast cancer
T. De Marchi, Erasmus MC, Rotterdam
- 18.00 Dinner**
- 20.00 **Keynote Lecture**

“Functions of metabolic reprogramming in cancer”

Dimitrios Anastasiou, MRC National Institute for Medical Research London, UK
- 21.00 **Disco** (sponsored by Bioke) and drinks

Wednesday November 5th, 2014

Session IV: DNA damage, stress and apoptosis

Chairs: Eric Eldering and Kasper Rouschop

- 9.00 *In situ* Rad51 foci formation assay as a tool to study PARP inhibitor-resistance in Brca1/2-deficient mouse mammary tumors
E. Gogola, NKI, Amsterdam
- 9.15 Lysophospholipids secreted by splenic macrophages induce chemotherapy resistance via interference with the DNA damage response
J.M. Houthuijzen, UMCU, Utrecht
- 9.30 GABARAPL1 mediates hypoxia-induced growth factor secretion through extracellular vesicles
T. Keulers, UMCM, Maastricht
- 9.45 Evaluation of Extrinsic and Intrinsic Cues Involved in BCR-ABL-Induced Leukemogenesis
P. Sontakke, UMCG, Groningen
- 10.00 Radiosensitization through autophagy-inhibition; fact or artefact?
M. Schaaf, UMCM, Maastricht
- 10.15 Tumor suppressor IKZF1 mediates glucocorticoid therapy resistance in B-cell precursor ALL
R. Marke, Radboudumc, Nijmegen
- 10.30 Coffee/Tea**

Session V: Stem cells

Chairs: Jan Jacob Schuringa and Renee van Amerongen

- 11.00 Salinomycin, a novel cancer stem cell- targeting compound in bladder carcinoma?
G. van der Horst, LUMC, Leiden
- 11.15 IGFBP7 eradicates leukemic stem and progenitor cells in acute myeloid leukemia
H. Verhagen, VUMC, Amsterdam
- 11.30 Lgr5+ and Lgr6+ stem cells and their progeny in the skin after UV exposure
G. van de Glind, LUMC, Leiden
- 11.45 Wnt signaling and breast cancer: Dissecting the responses of the mammary epithelium to elevated Wnt/beta-catenin signaling
A. Zeeman, VUMC, Amsterdam
- 12.00 **BIOKE presentation:**
"PathScan® Antibody Array Kits: slide-based assays using the sandwich ELISA principle"
Edward Verwayen

12.15-13.15 lunch

- 13.15 **Invited Lecture**
"Determining Cell Fate after DNA Damage"
Rene Medema, NKI-AVL, Amsterdam

Session VI: Invasion and metastasis

Chairs: Erik Danen and Patrick Derksen

- 14.00 TRPM7 maintains mesenchymal phenotype of breast cancer cells by mechanoregulation of SOX4 expression
A. Kuipers, Radboudumc, Nijmegen
- 14.15 Loss of p120-catenin induces a non-genetic route to aneuploidy in cancer
R. van de Ven, UMCU, Utrecht
- 14.30 Coffee/Tea**
- 15.00 Adhesion signaling in control of breast cancer growth, migration, and metastasis
J. Xiong, LACDR, Leiden
- 15.15 An imaging-based tumor cell migration phenotypic RNAi-screen to identify novel candidate metastasis genes
M. Fokkelman, LACDR, Leiden
- 15.30 *In vivo* imaging of invasive ductal carcinoma reveals that epithelial-mesenchymal transition is not required for migration and dissemination of primary tumor cells but provides a metastatic outgrowth advantage
D. Seinstra, Hubrecht Institute, Utrecht
- 15.45 **Best presentation awards and closure**

